Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP2A | P11388 | 4/20 | 0.46 |
| ▸ | HSP90AB1 | P08238 | 3/20 | 0.46 |
| ▸ | CHEK1 | O14757 | 4/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.44 |
| ▸ | FLT3 | P36888 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA3 | P07451 | 1/20 | 0.41 |
| ▸ | CA6 | P23280 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.41 |
| ▸ | BCL6 | P41182 | 1/20 | 0.41 |
| ▸ | BCOR | Q6W2J9 | 1/20 | 0.41 |
| ▸ | DDR1 | Q08345 | 2/20 | 0.41 |
| ▸ | PRKD1 | Q15139 | 2/20 | 0.39 |
| ▸ | PRKD2 | Q9BZL6 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6154711 | 0.95 | TOP2A (0.47) | TOP2AHSP90AB1CA1CA2CA3 | |
| SCHEMBL6153360 | 0.90 | CHEK1 (0.53) | TOP2AHSP90AB1CHEK1KCNH2FLT3 | |
| SCHEMBL6156929 | 0.87 | MAPK14 (0.47) | TOP2AHSP90AB1CHEK1KCNH2FLT3 | |
| SCHEMBL6153883 | 0.86 | CHEK1 (0.50) | TOP2AHSP90AB1CHEK1KCNH2FLT3 | |
| SCHEMBL6156066 | 0.80 | TOP2A (0.43) | TOP2AHSP90AB1 | |
| SCHEMBL6154502 | 0.80 | ROCK2 (0.51) | CHEK1FLT3CA1CA2CA3 | |
| SCHEMBL6154499 | 0.80 | ROCK2 (0.51) | CHEK1FLT3CA1CA2CA3 | |
| SCHEMBL6153952 | 0.80 | DDR1 (0.53) | TOP2AHSP90AB1DDR1 | |
| SCHEMBL6155256 | 0.79 | TOP2A (0.42) | TOP2AHSP90AB1PRKD1PRKD2 | |
| SCHEMBL6154879 | 0.79 | BRD4 (0.47) | TOP2AHSP90AB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050182040-A1 | Benzamide derivatives | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2005-08-18 | — | — | US | disclosed |
| EP-1500643-A1 | BENZAMIDE DERIVATIVES | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2005-01-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050182040-A1 | Benzamide derivatives | ROCK1, ROCK2, NHERF1 | TOP2A 4307/4885HSP90AB1 1463/4885CHEK1 2194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.